Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
-1.1%
$0.01
$0.00
$0.04
N/AN/A100,005 shs85,513 shs
SXTPW
60 Degrees Pharmaceuticals
$0.06
+11.6%
$0.06
$0.01
$0.10
N/AN/A17,191 shs1,322 shs
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
$0.00
$0.00
$0.00
N/AN/A185,753 shs445,000 shs
TRSBF
3SBio
$2.95
$1.78
$2.22
$3.35
N/AN/A686 shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00%+2.35%+16.00%0.00%-16.35%
SXTPW
60 Degrees Pharmaceuticals
0.00%+9.23%+13.60%+115.97%-18.86%
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
0.00%-3.59%-1.67%+256.32%+284.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
$665.45KN/AN/AN/AN/AN/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
SXTPW
60 Degrees Pharmaceuticals
N/A
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
N/A
TRSBF
3SBio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable
Tetra Bio-Pharma Inc. stock logo
TBPMF
Tetra Bio-Pharma
33N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0087 0.00 (-1.14%)
As of 06/20/2025 03:42 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.06 +0.01 (+11.59%)
As of 06/20/2025 01:58 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Tetra Bio-Pharma stock logo

Tetra Bio-Pharma OTCMKTS:TBPMF

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

3SBio OTCMKTS:TRSBF

$2.95 0.00 (0.00%)
As of 06/20/2025

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.